Compare A & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | A | EW |
|---|---|---|
| Founded | 1999 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.8B | 46.0B |
| IPO Year | 1999 | 1999 |
| Metric | A | EW |
|---|---|---|
| Price | $119.90 | $85.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 21 |
| Target Price | ★ $165.13 | $96.47 |
| AVG Volume (30 Days) | 1.9M | ★ 4.8M |
| Earning Date | 05-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.82% | N/A |
| EPS Growth | ★ 3.16 | N/A |
| EPS | ★ 4.57 | 1.83 |
| Revenue | $4,472,000,000.00 | ★ $6,067,600,000.00 |
| Revenue This Year | $8.03 | $13.19 |
| Revenue Next Year | $6.22 | $9.81 |
| P/E Ratio | ★ $27.29 | $49.94 |
| Revenue Growth | 6.43 | ★ 11.55 |
| 52 Week Low | $96.43 | $65.94 |
| 52 Week High | $160.27 | $87.89 |
| Indicator | A | EW |
|---|---|---|
| Relative Strength Index (RSI) | 28.83 | 63.52 |
| Support Level | $115.37 | $81.61 |
| Resistance Level | $123.79 | $87.20 |
| Average True Range (ATR) | 3.37 | 2.39 |
| MACD | -0.27 | 0.92 |
| Stochastic Oscillator | 3.89 | 99.17 |
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.